Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research
Activity Outline
Topics in Public Health: Health Disparities among AAPI Populations: An Overview and Examples in Cancer Health
January 20, 2023
Webinar

Activity Coordinators:
Amy Ramanadham (Amy.Ramanadham@fda.hhs.gov),  Jessica Voqui (Jessica.Voqui@fda.hhs.gov)
Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description
This presentation will provide an overview of health disparities and inequities in Asian American and Pacific Islander (AAPI) populations, describe cancer burden and screening in AAPI populations, and discuss cervical cancer screening efforts in US-affiliated Pacific Islands.
References
  • Health Care Disparities Among Asian, Native Hawaiian, and Other Pacific Islander (NHOPI) People, KFF, May 27, 2022. https://www.kff.org/racial-equity-and-health-policy/issue-brief/health-care-disparities-among-asian-native-hawaiian-and-other-pacific-islander-nhopi-people/
  • Richard J. Lee, Ravi A. Madan, Jayoung Kim, Edwin M. Posadas, Evan Y. Yu, Disparities in Cancer Care and the Asian American Population, The Oncologist, Volume 26, Issue 6, June 2021, Pages 453–460, https://doi.org/10.1002/onco.13748
Series Objectives
  • Increase awareness of current topics in public health
  • Help improve patient/public health outcomes
  • Help participants modify their practice within their job or deployments
Learning Objectives After completion of this activity, the participant will be able to:
  • Identify a couple of health disparity examples in AAPI populations
  • Describe cancer burden and screening in AAPI populations
  • Discuss health-related barriers and opportunities in AAPI populations
Target Audience
This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, This activity is intended for physicians, pharmacists, nurses, and and other public health medical professionals interested in learning more about the initiatives other advances in public health..
Agenda

Lecture 1 January 20, 2023
Time Topic Speaker
2:00 - 3:00 PM EST Health Disparities among AAPI Populations: An Overview and Examples in Cancer Health Graydon Yatabe, MPH, RDN
Jin Qin, D.Sc, MS
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-23-016-L99-P, and ACPE Universal Activity Number JA0002895-0000-23-016-L99-T for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
CPH
Up to 1.00 CPH Recertification Credits may be earned at this event.
Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Disclosure

Faculty
  • Qin, Jin, D.Sc, MS, Epidemiologist, CDC - nothing to disclose
  • Yatabe, Graydon, MPH, RDN, N/A, N/A - nothing to disclose

Planning Committee
  • Birch-Smith, Postelle, PharmD, Lead CSO, FDA - nothing to disclose
  • Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - nothing to disclose
  • Herber, Kari, RN, Regional Program Manager, Department of Homeland Security - nothing to disclose
  • Janusziewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OUDLC - nothing to disclose
  • La, Thang, PharmD, MPH, Central Triage Unit Manager, FDA/CDER/OSE/RSS - nothing to disclose
  • McClain, Rena, PharmD, Health Insurance Specialist, CMS - nothing to disclose
  • Nabavian, Sadaf, PharmD, Senior Regulatory Project Manager, FDA - nothing to disclose
  • Radden, Erica, MD, Medical Officer, USPHS/DHS/USCG - nothing to disclose

CE Consultation and Accreditation Team
  • Harrison, Catherine, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
  • Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Any relationship shown above in italics has been divested within the last 24 months and is therefore considered mitigated.
All relevant financial relationships have been mitigated.
Registration Information
Registration is complimentary; therefore refunds are not applicable.